Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BEBT-908 + rituximab + ifosfamide + carboplatin + etoposide
- Development stage
- Unknown
- Lead developer
- BeBetter Med
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A five-drug combination therapy consisting of **BEBT-908** (a dual PI3K/HDAC inhibitor), **rituximab** (an anti-CD20 monoclonal antibody), **ifosfamide** (an alkylating agent), **carboplatin** (a platinum-based DNA crosslinker), and **etoposide** (a topoisomerase II inhibitor). BEBT-908 inhibits both phosphoinositide 3-kinase (PI3K) signaling and histone deacetylase (HDAC) activity, producing anti-tumor activity, promoting ferroptosis, and downregulating c-Myc. Rituximab targets CD20+ B lymphocytes for selective cytotoxicity. Ifosfamide, carboplatin, and etoposide are standard chemotherapeutic agents providing DNA damage and cytostatic effects. This regimen is under investigation for relapsed/refractory diffuse large B-cell lymphoma (DLBCL)[1][2][3].
- Other names
- R-ICE (as regimen)BEBT-908 combined with rituximab-ifosfamide-carboplatin-etoposideBEBT908 combined with rituximab-ifosfamide-carboplatin-etoposideBEBT 908 combined with rituximab-ifosfamide-carboplatin-etoposide
02
Targets
HDAC10 (Histone Deacetylase 10)CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)PIK3CA (Phosphoinositide 3-kinase alpha)DNA
Beyond the preview
Go deeper on BEBT-908 + rituximab + ifosfamide + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BEBT-908 + rituximab + ifosfamide + carboplatin + etoposide.